Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is set to announce second quarter earning results on Monday 3rd August 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, NBIX to report 2Q20 income of $ 0.73 per share.
For the full year, analysts anticipate top line of $ 1073.05 million, while looking forward to income of $ 2.93 per share bottom line.
Previous Quarter Performance
Neurocrine Biosciences, Inc. unveiled income for the first quarter of $ 0.82 per share, from the revenue of $ 237.10 million. The quarterly revenues grew 71.32 percent compared with the same quarter last year. The consensus estimates are income of $ 0.54 per share from $ 223.87 million in revenue. The bottom line results beat street analysts by $ 0.28 or 51.85 percent, at the same time, top line results outshined analysts by $ 13.23 million or 5.91 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Neurocrine Biosciences, Inc.
Stock Performance
According to the previous trading day, closing price of NBIX was $ 120.36, representing a 66.84 % increase from the 52 week low of $ 72.14 and a 11.67 % decrease over the 52 week high of $ 136.26.
The company has a market capital of $ 11.18 billion and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”NBIX” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
- On 15th July 2020, maintained by Morgan Stanley at Overweight rating, with $ 149.00 target price.
- On 29th June 2020, downgraded by Goldman Sachs Group to Neutral from Buy rating.
- On 18th June 2020, maintained by JPMorgan Chase & Co. at Overweight rating, with $ 134.00 target price.
- On 17th June 2020, maintained by HC Wainwright at Buy rating, with $ 131.00 target price.
- On 10th June 2020, maintained by Canaccord Genuity at Buy rating, with $ 134.00 target price.
Conference Call
Neurocrine Biosciences, Inc. will be hosting a conference call at 4:30 PM eastern time on 3rd August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.neurocrine.com
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in womens health.
